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Introduction
Human tissue largely consists of heterogeneous cell populations with varying properties. A major focus of biological research is to understand the contribution of specific cell populations in normal homeostasis and response to disease. Subpopulations of cells are commonly identified by immunological labeling or by genetic tagging with reporter proteins such as GFP. [1] Once identified, these cells are often purified by fluorescence activated cell sorting (FACS). However, such methods require prior knowledge of surface markers or genes specific to the targeted subpopulations of cells.
In addition, the dependence on these specific factors may introduce an inherent bias when attempting to perform broad analysis of a cell type. For example, some techniques for circulating tumor cell (CTC) isolation depend on the epithelial marker EpCAM, but recent studies have also demonstrated the presence and biological significance of EpCAM-negative CTCs. [2, 3] Indeed it is still largely unknown which subset of CTCs is responsible for metastasis or which surface markers best characterize such cells.
Methods have been developed to isolate cells based on their physical properties such as size, deformability and photoacoustic properties, thus bypassing the use of cell surface markers and genes. [4] [5] [6] [7] Techniques based on physical properties have the potential to overcome biases inherent to marker or gene-based methods. While the selective tagging or manipulation of target cells within a mixture of cells is of great value for research, diagnostics and therapeutics, the physical properties of cells have yet to be used as differentiating factors for selective delivery of payload to cells.
Current methods for selective delivery largely rely on interactions at the surfaces of cells, such as ones dependent on electrostatic properties and hydrogen bonds, or cell surface receptors and molecules, such as the cluster of differentiation molecules and proteoglycans. [8, 9] Moreover, these methods rely on endocytosis or pinocytosis for delivery, which can lead to subsequent undesired lysosomal degradation of all or significant portions of the delivered payload. The efficacy of these delivery methods can be enhanced by decreasing lysosomal degradation or avoiding lysosomal uptake, but perhaps the most effective way to reduce lysosomal degradation is to avoid the dependence on cell surface interactions altogether. [10] [11] [12] Methods that transiently induce cell membrane disruption allow diffusion of payload into the cells. A commonly employed technique of plasma membrane disruption is by means of electrical forces, such as electroporation. However, these electrical methods are limited by their inability to deliver materials selectively among a heterogeneous mixture of cells and are often restricted to nucleic acids.
A method for cytosolic delivery that is independent of surface-expressed markers on cells has been demonstrated using a microfluidic device that disrupts the cell membrane using mechanical forces as cells traverse through tight constrictions. [13] [14] [15] The delivery of a wide range of cargo sizes (3 kDa to 2 MDa) can be achieved with high efficiency and uniform distributions, suggesting that the size of holes resulting from the membrane disruption are homogeneous within that population of cells. [15, 16] While this transient disruption of the cell membrane allows for bi-directional movement of material across the membrane, cells areremain viable and retain their proliferative capacity and biological activityThis membrane disruption is transient and has no apparent effects on cell viability or function. [13, 15, 16, 18] Here we demonstrate the use of a microfluidic system to confer selective cytosolic delivery within a mixture of cells based on cell size. We further validated this approach by demonstrating size-selective delivery to the large circulating tumor cells found in the blood of pancreatic cancer patients, allowing for their identification and genomic analysis.
Results

Delivery approach
We previously described a microfluidic platform that allows intracellular delivery of macromolecules to cells based on membrane deformation. [15] We hypothesized that by selecting the appropriate deformation parameters, one could selectively disrupt the membrane of target cells while leaving those of non-target cells intact. To this end, we employed microfluidic chips comprising 75 parallel channels etched onto a silicon chip sealed by a Pyrex layer. [15] Each channel had a central constriction of a specific length and width. We posited that during transit through this constriction, the cell membranes would be disrupted by mechanical deformation and this temporary disruption would facilitate diffusion of small molecules into the cytoplasm of the cells. The degree of deformation is a function of the cell diameter relative to constriction width. Fig. 1 illustrates the effect encountered by cells of different sizes as they traverse through a constriction of specific width.
To evaluate the size-selectivity of the delivery platform, we employed cells with different average cell diameters: primary human T-cells (6.7 µm) and two pancreatic cancer cell lines BxPc3 (10.8 µm) and PANC-1 (12.3 µm) ( Fig. 2A) . A suspension of each cell type along with a fluorophore-conjugated macromolecule (cascade blue-conjugated 3 kDa dextran polymer) was delivered through devices with varying constrictions (4 to 9 µm wide). Endocytic uptake and surface binding are not observed when cells are incubated with the fluorophore-conjugated dextran polymer (data not shown). [13, 15] However, efficient intracellular delivery of the dextran polymer occurs after passage through the microfluidic device (Supplemental Fig. S1 ). The percentage of cells with intracellular dextran was determined using FACS based on the fluorescence of the labeled dextran. Constrictions that were several micrometers less than the average width of the cell allowed the maximum delivery of the dextran polymer (Fig. 2B) . For example, an average of 85.5% T-cells received intracellular dextran when the constriction was 4 µm. As the constriction width increased, the average delivery progressively decreased to less than 12% when the constriction exceeded the average diameter of the T-cells (≥7 µm constriction widths compared to cell diameters of 6. Interestingly, we also observed poor delivery of intracellular dextran in BxPc3 and PANC-1 cells when the constriction width was very narrow. To determine the mechanism of this effect, cell viability was measured using the viability dye propidium iodide (PI).
These experiments demonstrated that the narrower constrictions lowered cell viability and, as a result, there was an optimal range of widths for the constriction for which maximum cell viability and dextran delivery were achieved for each cell type (Fig. 2B) . As these experiments demonstrate, the constriction widths that maximize delivery and cell viability are not necessarily the same, and therefore one must balance these two objectives. To determine the optimal channel sizing we developed a metric called delivery efficacy, a product of delivery (%) and viability (%). The highest delivery efficacy was achieved with a 4 µm-wide constriction for T-cells (Fig. 2D) , with an average delivery of 85.3% and average viability of 73.5% when delivered at 50 psi (Supplemental Fig. S2 ), and average delivery of 85.5% and average viability of 51.0% when delivered at 100 psi (Fig. 2B) . Since the BxPc3 and PANC-1 cells were close in cell diameter, their optimal constrictions were similar, 6 µm or 7 µm wide, depending on the delivery pressure (Fig.   2D ). As noted in a previous study, the applied pressure also affected the delivery efficacy ( Fig. 2C and 2D ). [15] We observed that higher pressure correlated with higher delivery but lower viability for a given constriction width (Supplemental Fig. S2 ). When the constriction width was narrower than its optimal value for a given cell size, the higher delivery pressure likely led to extensive membrane disruption that was beyond the ability of the cell to repair and reseal.
We then assessed the cell size selectivity of the microfluidic device in a heterogeneous cell population. In order to verify the size-selective delivery in a mixed population, these experiments required one cell population to express a marker that would readily allow for the differentiation of the two cell types by FACS. The PANC-1 cells employed here express GFP, and thus could be differentiated from the T-cells during FACS based on their green fluorescence. While BxPc3 cells were not analyzed in these experiments, BxPc3 and PANC-1 cells share a common effective constriction width and therefore we would expected these cells to exhibit a similar performance in these experiments. A suspended mixture of T-cells and PANC-1 cells along with the cascade blue-conjugated 3 kDa dextran fluorophore was passed through the device using chips with different constriction widths. PANC-1 cells employed in these studies expressed GFP and thus could be differentiated from the T-cells during FACS based on their green fluorescence. As expected, the constriction width that allows for maximum fluorophore delivery for each cell type remained the same ( Fig. 2E and 2F ).
Interestingly, the delivery into T-cells was low when delivered together with PANC-1 cells as compared to when delivered alone, even at their optimal constriction width of 4 µm (39.0% versus 85.5% delivery at 100 psi, respectively). The reason is unknown, but since we noticed that the flow rate within the chip was reduced during delivery, we hypothesize that the flow characteristics within the chip may have been altered due to accumulation of debris from the PANC-1 cells that were destroyed while traversing through constriction widths that were too narrow for their cell diameter. Importantly, at their optimal constriction width, larger cells achieved fluorophore delivery at a significantly higher percentage than smaller cells; relative to T-cells, delivery into PANC-1 cells was 14-fold higher with 6 µm wide constrictions and 82-fold higher with 7 µm wide constrictions. 
Selective delivery to circulating tumor cells
CTCs are the rare tumor cells found in the bloodstreams of cancer patients and believed to be responsible for metastasis. [19] Numerous methods have been developed to detect or enrich CTCs based on size or surface-expressed markers, but none have demonstrated selective intracellular delivery to CTCs. Such an approach could have a range of implications for research, diagnostics, and therapeutic development.
Considering our ability to label specific cell types within a heterogeneous population, we explored whether we could selectively deliver material to CTCs directly.
To assess the potential performance of our approach for labeling tumor cells in clinical samples, healthy patient whole blood was spiked with various amounts of GFPexpressing PANC-1 cells. These samples were depleted of red blood cells by lysis, resulting in a cell suspension consisting primarily of leukocytes and PANC-1 cells. This cell suspension was mixed with a tetramethylrhodamine-conjugated 10 kDa dextran fluorescent dye and passed through a chip whose constrictions were 7 µm wide (Fig. 3A) .
Tetramethylrhodamine-conjugated dextran was chosen for these experiments for compatibility with downstream FACS analysis; while larger than the 3kDa cascade blueconjugated dextran employed earlier, delivery efficiency is not affected by the molecular weight of dextran. [15, 16] GFP expression in PANC-1 cells provided an independent signal to confirm successful labeling of tumor cells. To further enhance the selectivity of the method, cells were stained with an antibody specific to CD45 to exclude contaminating dextran-positive leukocytes during FACS sorting. Analysis of the treated samples by FACS indicated that most of the cells in the high dextran, low CD45 region also displayed high green fluorescence, indicating that we were able to deliver the tetramethylrhodamine dextran selectively into the GFP-expressing PANC-1 cells with high specificity. S4 ). Preferential amplification of alleles in whole-genome amplification by MDA limits the ability to estimate the fraction of tumor cells relative to normal cells based purely on alternate and reference allele counts. [21] Nonetheless, the identification of the KRAS and p53 variants found in PANC-1 cells within the cell population isolated based on intracellular tetramethylrhodamine dextran demonstrate the capability of the sizeselective delivery method to sort CTCs based on high dextran, low CD45 gates.
CTCs in patients are extraordinarily rare, with generally less than 10 cells found per ml of blood. [22] To illustrate the utility of this size-selective delivery method for targeting such rare cells, we processed blood from a patient with pancreatic duct adenocarcinomas (PDAC). A blood draw was obtained from a patient (HTB1760) prior to surgical resection of their tumor (Fig. 4A) . After RBC lysis, the remaining cells were processed through our microfluidic platform along with the tetramethylrhodamine-conjugated 10 kDa dextran polymer. Cells were sorted and recovered with both low and high purity gates, indicative of likely high and low leukocyte contamination by anti-CD45 antibody labeling respectively. Targeted sequencing of the recovered cells identified a missense mutation in TP53 (R209Q) in both high and low purity samples (Fig. 4B ) that was absent in the bulk gDNA from the blood. The genetic alterations found in CTCs have been demonstrated to accurately reflect those of primary and metastatic tumors. [23] Therefore, parallel sequencing of DNA isolated from laser capture microdissected cells from the primary tumor was performed to validate the nature of the size-selected cells. This analysis revealed the same TP53 mutation in the primary tumor, confirming that tumor cells were present among the recovered population.
Discussion
The work described here demonstrates the ability of a physical property such as The microfluidic device has demonstrated applicability in delivering a variety of materials with a wide range of sizes that are retained by the cells, allowing for the manipulation of their biological properties. [13, 15, 16, 18, 24] Here, our use of in vitro CTC models and clinical PDAC patient samples has demonstrated the additional utility of this platform to selectively deliver payload within a heterogeneous population of cells.
Moreover, this method may be of particular benefit for delivering payloads that are sensitive to endocytic degradation as the direct delivery of payloads into the cytosol bypasses the endosomal uptake processes and thus expands one's ability to manipulate cell function. [14] The underlying intracellular delivery technique thus has the potential to facilitate co-delivery of intracellular probes and/or functional materials to enable in vitro and ex vivo cell manipulation. [13] [14] [15] Despite the aforementioned advantages of this delivery platform, it does have a few
limitations. Recent studies have demonstrated that mechanical stresses imparted by passage through microfluidic channels can disrupt the nuclear membrane and induce DNA damage. [25, 17] Although not a focus of our prior analysis, we have not observed loss of nuclear integrity or cell function when cells are run on our platform. [13, 15, 18] It is likely that the larger channels contained in our device do not have significant effects on the nuclear membrane. However, investigation of nuclear integrity may be necessary for studies in which long-term growth of cells is required. There may also be unique situations where analysis of select cellular pathways may be obscured shortly after cytoplasmic membrane disruption. The rapid and Ca+-dependent restoration of cell membrane integrity after passage through the microfluidic device is consistent with active membrane repair. [16, 17] This mechanism Active membrane repair largely occurs by mechanisms involvesing vesicular transport, [26] and while there does not appear to be any long-term biological consequences of these events, components of these pathways may be diverted from their normal cellular functions shortly after delivery of payload.
In its current manifestation, if the difference in cell diameters between subpopulations is too small, the device cannot provide differentiating cytosolic delivery.
Another apparent constraint is that only the larger cell population can receive cytosolic materials within a heterogeneous mixture. This constraint is because a chip sized to preferentially deliver to the smaller population would likely lyse the larger population, or potentially clog (Fig. 2B) . Nevertheless, one can envision step-wise isolation and cytosolic delivery sequentially from larger to smaller cells within a heterogeneous cell population using consecutively smaller constriction widths with each treatment through the device. Finally, there may be other unexamined properties that could affect delivery efficacy. For example, cell stiffness and shape (e.g. spherical vs bi-concave), as well as chemical properties such as hygroscopic effects and electrostatic interactions may have significant impacts on delivery performance and these areas could be the subject of future studies.
Conclusion
The microfluidic device described here expands the scope of properties that can be exploited for identifying and manipulating cells. Size-selective cytosolic delivery is not only a unique approach, but also provides several potential advantages over current methods of delivery. There are inherent limitations to the technique, but the advantages offered over existing systems have some important implications. We demonstrated its ability to tag with high specificity in in vitro CTC models and in vivo patient samples. This size-dependent method decreases selection bias inherent to surface marker-dependent methods and introduces a method of separating and manipulating cells when cell surface markers and genotype are not known a priori. By allowing one to combine immunological information with size-selective delivery, this approach could potentially enable novel approaches to diagnostics and drug discovery.
Experimental Section Cell culture
The BxPc3 and GFP-expressing PANC-1 cell lines were cultured in DMEM (11965118, ThermoFisher Scientific) with 10% FBS (ThermoFisher Scientific) and 1% Penicillin- 
T-cell isolation
Primary T-cell populations were obtained from fresh healthy human whole blood RCF for 5 minutes and prepared for FACS as described below. Two negative controls were employed for these experiments: 1) RBC-depleted whole blood that was not spiked with PANC-1 cells was incubated with the dextran dye and processed through the microfluidic delivery platform to establish delivery of dye into leukocytes and 2) GFPexpressing PANC-1 cells incubated with the dextran dye, but not processed through the microfluidic delivery platform, to establish the basal levels of surface receptor-mediated binding and non-specific uptake of dye.
Patient sample
Whole blood was obtained from a patient (HTB1760) undergoing a Whipple resection of a moderately differentiated pancreatic ductal adenocarcinoma after obtaining informed consent in accordance with the Massachusetts General Hospital institutional review board. Blood was processed as described above in the "CTC cell spike" section. Cells from a formalin fixed paraffin embedded sample of the resected tumor were isolated by laser capture microdissection at the Advanced Tissue Resources Core at the Massachusetts General Hospital. *denotes low coverage.
